Medarex has intitiated phase 2 clinical trial of FG-3019 in patients with type 2 diabetes and advanced kidney disease. In this regard, Medarex will receive a milestone payment of an undisclosed amount from its licensing partner, FibroGen.
FG-3019 is a fully human monoclonal antibody generated using Medarex’s UltiMAb technology against connective tissue growth factor (CTGF).
Medarex would receive future milestone payments and sales-based royalty payments, under the agreement.
Howard Pien, Chairman and CEO of Medarex, said: “We are pleased with the progress our licensing partners continue to make in the development of antibodies generated from our UltiMAb technology.”
“We believe the advancements of other antibody programs generated from Medarex’s UltiMAb platform will continue to emphasize the therapeutic importance of our technology to address underserved medical needs,” he added.
What is Type 2 Diabetes?
Type 2 diabetes is the most common form of diabetes. In type 2 diabetes, either the body does not produce enough insulin or the cells ignore the insulin. Insulin is necessary for the body to be able to use glucose for energy. When you eat food, the body breaks down all of the sugars and starches into glucose, which is the basic fuel for the cells in the body. Insulin takes the sugar from the blood into the cells. When glucose builds up in the blood instead of going into cells, it can cause two problems:
- Right away, your cells may be starved for energy.
- Over time, high blood glucose levels may hurt your eyes, kidneys, nerves or heart.
Finding out you have diabetes is scary. But don’t panic. Type 2 diabetes is serious, but people with diabetes can live long, healthy, happy lives.
While diabetes occurs in people of all ages and races, some groups have a higher risk for developing type 2 diabetes than others. Type 2 diabetes is more common in African Americans, Latinos, Native Americans, and Asian Americans/Pacific Islanders, as well as the aged population.
Thus we will be wishing success for Medarex in the upcoming trials.
Filed under Diabetes, Diabetes Drug, Diabetes Drugs, Diabetes awareenss, Featured Article, IDDM, NIDDM, World | Tags: connective tissue growth factor, monoclonal antibody, phase2 clinical trial, type 2 diabetes | Comment Below